Get the Stockscreener App
10.59
1.21%
-0.13
After Hours:
10.78
0.19
+1.79%
Tonix Pharmaceuticals Holding Corp stock is traded at $10.59, with a volume of 582.83K.
It is down -1.21% in the last 24 hours and down -15.62% over the past month.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
See More
Previous Close:
$10.72
Open:
$10.93
24h Volume:
582.83K
Relative Volume:
1.13
Market Cap:
$181.63M
Revenue:
$13.11M
Net Income/Loss:
$-124.02M
P/E Ratio:
-0.7426
EPS:
-14.261
Net Cash Flow:
$-107.25M
1W Performance:
-8.86%
1M Performance:
-15.62%
6M Performance:
-29.40%
1Y Performance:
-60.46%
1-Day Range:
$10.48
$11.19
1-Week Range:
$10.48
$12.14
52-Week Range:
$9.40
$27.27
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
10.59 | 203.58M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - marketbeat.com
Could Market Volatility Test Tonix Pharmaceuticals (NASDAQ:TNXP)? - Kalkine Media
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com Canada
Q3 EPS Estimate for Tonix Pharmaceuticals Raised by Analyst - marketbeat.com
What macro factors could move Tonix Pharmaceuticals (NASDAQ:TNXP) shares this week? - Kalkine Media
Tonix Pharma Appoints New Chief Commercial Officer - The Globe and Mail
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Passes Above Two Hundred Day Moving AverageWhat's Next? - marketbeat.com
symbol__ Stock Quote Price and Forecast - CNN
Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer - Minichart
TNXP Looks 393.2% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 - marketscreener.com
Why is Tonix Pharmaceuticals (NASDAQ:TNXP) stock in focus as Wall Street reopens today? - Kalkine Media
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer - Yahoo Finance
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
TNXP|Tonix Pharmaceuticals Holding Corp|Price:13.140|Chg%:-0.230 - TradingKey
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26 - Yahoo Finance
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference - GlobeNewswire
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock - MarketBeat
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock - Investing.com
Tonix Pharma (NASDAQ: TNXP) CEO adds 2,000 shares in IRA - stocktitan.net
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Canada
Tonix Pharmaceuticals director bagger buys $12,600 in stock - investing.com
Tonix (TNXP) Market: Adds 1.29% to Close at $12.55; the Near-Term Reference Band Stretches From $11.92 to $13.18 in the Latest ReadingPositive Gamma - siam.in
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript - AOL.com
Tonix Pharma Names CEO Seth Lederman Interim CMO - The Globe and Mail
Tonix (TNXP) Daily Snapshot: Finishes 0.16% Higher at $12.68 in Latest Trading; the $12.05 to $13.31 Range Remains in Focus under the Current SnapshotValue Area High - Vinanet
Why TNXP Stock Is Suddenly Back On Retail Radar - stocktwits.com
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline - MarketBeat
Tonix Pharmaceuticals (TNXP) Holds Ground at $12.66 as Traders Eye $13.29 ResistanceTrend Reversal Picks - vinanet.vn
Tonix Pharmaceuticals Holding Corp. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TNXP) 2026-08-14 - Seeking Alpha
Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants - Stock Titan
AQR Capital discloses 5.54% ownership in Tonix Pharmaceuticals (TNXP) via Schedule 13G - Stock Titan
TNXP Q2 2026 Earnings: Better-Than-Expected Loss per Share, Shares Dip 3%Guidance Accuracy Score - Vinanet
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Tonix Pharmaceuticals Holding Corp.Common Stock (NQ: TNXP - FinancialContent
Industry Analysts Just Made A Dazzling Upgrade To Their Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Revenue Forecasts - Moomoo
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance UK
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build By Investing.com - Investing.com UK
Tonix Pharmaceuticals (TNXP) Revenue Surge Meets Persistent Cash Burn Concerns - simplywall.st
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build - Investing.com India
Tonix Pharmaceuticals: TONMYA Refills Surge 207% As Coverage Reaches 136 Million U.S. Lives - Pulse 2.0
Tonix Pharma earnings beat by $0.27, revenue topped estimates - Investing.com Nigeria
Tonix Delivers A Beat, But The Real Test Starts Now (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BAGGER RICHARD H | Director |
Aug 20 '26 |
Buy |
12.60 |
1,000 |
12,600 |
1,000 |
| Taylor Carolyn E. | Director |
Jun 12 '26 |
Buy |
10.55 |
1,415 |
14,928 |
1,833 |
| Stillwell Richard Newcomb | Director |
Jun 08 '26 |
Buy |
11.65 |
5,000 |
58,250 |
5,000 |
| LEDERMAN SETH | Chief Executive Officer |
Jun 09 '26 |
Buy |
11.79 |
5,000 |
58,950 |
9,005 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 31 '26 |
Buy |
12.62 |
5,000 |
63,100 |
20,001 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 18 '26 |
Buy |
14.89 |
15,000 |
223,350 |
15,001 |
0.14%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):